Breaking News

AbbVie Acquires Cerevel Therapeutics

Strengthens its foundation in neuroscience and positions itself to deliver sustainable long-term performance.

Author Image

By: Charlie Sternberg

Associate Editor

AbbVie has completed its acquisition of Cerevel Therapeutics for approximately $8.7 billion—strengthening its foundation in neuroscience and positioning itself to deliver sustainable long-term performance.   “Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie,” said Robert A. Michael, chief executive officer, AbbVie.   There are multi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters